Self-Assembling Peptide Adjuvants for Vaccine Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, especially those for modified live vaccines, often cause adverse reactions and are limited in effectiveness, necessitating the development of safer and more potent adjuvants that can enhance immune responses without toxic side effects.
Innovation Solution
The development of peptide-based adjuvants comprising a hydrophobic, turning, and hydrophilic region, specifically designed to self-assemble into hydrogels that can be used in conjunction with vaccines to enhance immunological responses, utilizing amino acid sequences like FLIVIGSIIGPGGDGPGGD, which form stable nanofibers and hydrogels that act as immunopotentiating agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants (aluminum hydroxide, oil emulsions, microbial derivatives) are used to enhance immune response, then vaccine effectiveness is improved, but adverse reactions and toxicity increase
Solution Approach 1:
The patent changes the chemical and physical parameters of adjuvants by using peptide-based materials with specific amino acid sequences (e.g., RADA16, FLIVIGSIIGPGGDGPGGD) that self-assemble into hydrogels with controlled mesh sizes, rheological properties, and degradation rates, thereby achieving enhanced immune response with reduced toxicity compared to traditional adjuvants
Solution Approach 2:
The patent creates composite vaccine formulations by combining peptide-based hydrogel adjuvants with antigens, where the hydrogel matrix provides both immunostimulatory properties and controlled antigen release, achieving synergistic effects that improve vaccine effectiveness while minimizing adverse reactions
2Reliability
If adjuvants are used with modified live vaccines to boost immune response, then vaccine potency is improved, but safety and biocompatibility deteriorate
Solution Approach 1:
The patent employs biodegradable peptide-based hydrogels that transiently provide adjuvant functionality during the critical immune response phase, then degrade into harmless amino acid components, offering short-term immunostimulation without long-term safety concerns
Solution Approach 2:
The patent optimizes the physical-chemical parameters of peptide adjuvants including molecular weight, amphiphilicity, and self-assembly kinetics to achieve potent immune stimulation with improved safety profile for modified live vaccine applications
3Reliability
If peptide adjuvants with complex self-assembling structures are designed to enhance immune response, then adjuvant efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes the self-assembling property of peptide sequences (e.g., RADA16, FLIVIGSIIGPGGDGPGGD) that automatically form hydrogel structures with appropriate mesh sizes and rheological properties when exposed to physiological conditions, eliminating the need for complex manufacturing processes to create the adjuvant structure
Solution Approach 2:
The patent performs preliminary computational design and in vitro validation of peptide sequences to predict self-assembly behavior and immunogenicity before synthesis, reducing manufacturing complexity by selecting sequences that naturally form the desired hydrogel structures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide adjuvants demonstrate improved immune response efficacy, as shown in H1N1 vaccine studies, with enhanced antibody production and biocompatibility, reducing injection site reactions and providing a safer alternative to traditional adjuvants.
Implementation Method 1
The peptide adjuvant comprises a peptide having a hydrophobic region, a turning region, and a hydrophilic region, with the turning region being between the hydrophobic and hydrophilic regions
Implementation Method 2
The peptide adjuvant comprises a peptide having a hydrophobic region, a turning region, and a hydrophilic region
Data Source
AI summary
Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent.